October 7, 2026
Houston, TX – October 8, 2026 – Vivifi Medical, a medical device company developing a minimally invasive, function-preserving treatment* for benign prostatic hyperplasia (BPH), today announced it has been named a finalist in MedTech Innovator’s (MTI) 2026 Early-Stage Grand Prize competition. The competition is the culmination of the world’s largest accelerator of medical technology companies.
MTI drew 1,835 global applicants for its 2026 Accelerator, which were evaluated by more than 500 subject-matter experts. Sixty-five companies made the cohort, 47 of them early-stage. Four of those 47 advanced to the Early-Stage Grand Prize finals: Feminai, Galenband, Urologic Health, and Vivifi.
As a finalist, Vivifi receives $25,000 in funding and will compete for the $350,000 Early-Stage Grand Prize at The MedTech Conference powered by AdvaMed in Boston. Tushar Sharma, PhD, Founder and CEO, will pitch on Tuesday, October 20, at 3:30 p.m. ET in the Keynote Theater, taking questions from a panel of industry experts from leading medtech companies. The conference audience votes live to select the winner.
BPH affects more than 660 million men worldwide, and in over 100 years there hasn’t been a fundamentally new way to treat it. Current procedures force patients to trade symptom relief for sexual and urinary side effects. Vivifi’s treatment* is designed to address the root cause of the disease, not just the symptoms. The approach is non-surgical, non-urethral, and function-preserving.
The selection builds on Vivifi’s earlier recognition this year. In May, the company joined the MTI 2026 Accelerator Cohort and was named to the inaugural MTI Index. In September, Pepperdine Graziadio named Vivifi one of 14 companies on its 2026 Most Fundable Companies® list, selected from more than 2,100 applicants across all 50 states.
“BPH affects more than 660 million men, and the standard of care still asks them to give something up to get relief. The finals put that problem in front of a room that knows medtech and votes live. We’re looking forward to making our case in Boston.” - Tushar Sharma, CEO of Vivifi Medical
Attending The MedTech Conference? The MTI Early-Stage Grand Prize finals are Tuesday, October 20, at 3:30 p.m. ET in the Keynote Theater.
Read MedTech Innovator’s announcement: MedTech Innovator Announces 2026 Grand Prize Finalists
About Vivifi Medical
Vivifi Medical is a Houston-based medical device company developing a minimally invasive, function-preserving treatment* for benign prostatic hyperplasia (BPH). Founded to make BPH care simpler and more humane, Vivifi combines expertise in urology, vascular medicine, and device design to create solutions that respect patient anatomy and quality of life. The company is headquartered in Houston, TX with an office in Portland, OR, and is currently in clinical investigation to evaluate the safety and effectiveness of its technology. Vivifi is committed to partnering with clinicians and investors who share its vision of better outcomes and faster recovery for men with BPH.
About MedTech Innovator
MedTech Innovator is the world’s largest accelerator of medical device, digital health, and diagnostic companies. Its mission is to improve human health by accelerating the growth of companies transforming patient care. MTI has been a catalyst for groundbreaking healthcare solutions, sourcing more than 20,000 applicants and fostering the growth of 838 graduates. Alumni have collectively raised $12 billion in follow-on funding, seen 65 acquisitions, and introduced 500+ products to the market, improving the health of millions worldwide. For more information about MedTech Innovator, its annual programs, portfolio of industry-leading startups, and insights on trends, visit MTI’s website, follow MTI on LinkedIn, and subscribe to its monthly newsletter.
Media Contact:
Tushar Sharma, CEO, Vivifi Medical
info@vivifimedical.com
2450 Holcombe Blvd, Ste 1420, Houston, TX 77021* NOTE: This treatment is for investigational use only and is not approved by the FDA for commercial distribution. It is currently under clinical investigation to evaluate its safety and effectiveness.
